A detailed history of China Universal Asset Management Co., Ltd. transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,722 shares of ACRS stock, worth $52,418. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,722
Previous 8,372 63.9%
Holding current value
$52,418
Previous $9,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$1.12 - $1.4 $5,992 - $7,489
5,350 Added 63.9%
13,722 $15,000
Q2 2024

Jul 19, 2024

SELL
$1.01 - $1.36 $5,307 - $7,146
-5,255 Reduced 38.56%
8,372 $9,000
Q1 2024

Apr 29, 2024

BUY
$0.92 - $1.44 $4,996 - $7,820
5,431 Added 66.26%
13,627 $17,000
Q4 2023

May 21, 2024

SELL
$0.64 - $6.49 $3,475 - $35,247
-5,431 Reduced 39.85%
8,196 $8,000
Q4 2023

Jan 23, 2024

BUY
$0.64 - $6.49 $4,084 - $41,419
6,382 Added 351.82%
8,196 $9,000
Q3 2023

May 21, 2024

BUY
$6.56 - $10.95 $5,825 - $9,723
888 Added 95.9%
1,814 $12,000
Q3 2023

Oct 30, 2023

BUY
$6.56 - $10.95 $5,825 - $9,723
888 Added 95.9%
1,814 $12,000
Q2 2023

May 21, 2024

BUY
$7.89 - $10.64 $181 - $244
23 Added 2.55%
926 $9,000
Q2 2023

Jul 27, 2023

BUY
$7.89 - $10.64 $181 - $244
23 Added 2.55%
926 $10,000
Q1 2023

May 21, 2024

BUY
$7.07 - $17.95 $1,590 - $4,038
225 Added 33.19%
903 $7,000
Q1 2023

Apr 27, 2023

BUY
$7.07 - $17.95 $1,590 - $4,038
225 Added 33.19%
903 $7,000
Q4 2022

May 21, 2024

SELL
$14.33 - $18.37 $185,559 - $237,873
-12,949 Reduced 95.02%
678 $10,000
Q4 2022

Jan 31, 2023

BUY
$14.33 - $18.37 $773 - $991
54 Added 8.65%
678 $11,000
Q3 2022

Oct 21, 2022

BUY
$13.07 - $18.22 $8,155 - $11,369
624 New
624 $10,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $255M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.